Baidu
map

Heart:维生素K和血管疾病

2018-12-05 xing.T MedSci原创

由此可见,与对照组相比,补充维生素K可显著降低VC,但不会降低VS。得出的结论受到少量具有实质异质性研究的限制。VKDP与CVD或死亡率的联合终点相关。有必要进行更大规模的临床试验,已确定补充维生素K改善VC、VS和长期心血管健康的功效。

血管硬化(VS)和血管钙化(VC)是与心血管事件相关的血管健康替代标志物。维生素K依赖性蛋白(VKDP)与VS和VC有关,需要维生素K才能发挥作用。近日,心脏病领域权威杂志Heart上发表了一篇研究文章,研究人员对以下几个方面进行了系统评价和荟萃分析:(1)补充维生素K对VS和VC的影响,以及(2)VKDP活性水平与心血管疾病和死亡率之间的关联。

两位研究者在MEDLINE和Embase数据库以及Cochrane和ISRCTN登记中心检索了维生素K临床试验的研究,这些试验是评估了对VC、VS或VKDP的影响,以及评估VKDP对CVD事件或死亡率影响的纵向研究。研究人员进行了随机效应荟萃分析。

13项对照临床试验(n=2162)和14项纵向研究(n=10726)符合预先规定的入选标准。与对照相比,维生素K补充与VC(-9.1%(95%CI为-17.7至-0.5); p=0.04)和VKDP(去磷酸-去羧化基质Gla蛋白; -44.7%(95%CI为-65.1至-24.3),p<0.0001)和未羧化骨钙蛋白(-12.0%(95%CI为-16.7至-7.2),p<0.0001)显著降低相关,但对VS无显著改善。在中位随访7.8(IQR为4.9-11.3)年的纵向研究中,VKDP水平与CVD或死亡率的综合终点相关(HR为0.45(95%CI为0.07至0.83),p=0.02)。

由此可见,与对照组相比,补充维生素K可显著降低VC,但不会降低VS。得出的结论受到少量具有实质异质性研究的限制。VKDP与CVD或死亡率的联合终点相关。有必要进行更大规模的临床试验,已确定补充维生素K改善VC、VS和长期心血管健康的功效。

原始出处:

Jennifer Susan Lees.et al. Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis.Heart.2018.http://dx.doi.org/10.1136/heartjnl-2018-313955

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
    2024-01-08 ms5151869221731898 来自天津

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
    2018-12-06 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
    2018-12-06 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
    2018-12-06 龙胆草

    学习谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2179949, encodeId=d0aa21e9949ec, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4c1850439, createdName=ms5151869221731898, createdTime=Mon Jan 08 11:49:56 CST 2024, time=2024-01-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1357014, encodeId=2856135e0147e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425720, encodeId=d2721425e20e8, content=<a href='/topic/show?id=8524e9083c6' target=_blank style='color:#2F92EE;'>#维生素K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79083, encryptionId=8524e9083c6, topicName=维生素K)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca0d3990423, createdName=bsmagic9133, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498503, encodeId=8b3b1498503e8, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563013, encodeId=1a09156301376, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Dec 06 23:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354601, encodeId=dae73546012f, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Dec 06 08:40:08 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354500, encodeId=d0e53545003e, content=了解,谢谢分亨!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdgSW0vVibEHQRlKXLlvMibvcHmy5ibwM7Luib2am6ywX6FqBrXibF8k7JVEzriaOSghltmYz1nomRd6TgSp2Yj9xHGAY/0, createdBy=9b2f2045808, createdName=haige, createdTime=Wed Dec 05 08:37:23 CST 2018, time=2018-12-05, status=1, ipAttribution=)]
    2018-12-05 haige

    了解,谢谢分亨!

    0

相关资讯

Clin Gastroenterol Hepatol:肝硬化门静脉血栓形成服用维生素K拮抗剂 出血风险知多少?

2018年7月,发表于《Clin Gastroenterol Hepatol》上的一项研究,考察了抗凝药对肝硬化和门静脉栓塞患者的利与弊。

JACC:口服维生素K拮抗剂房颤患者的预后研究

根据指南推荐,治疗时间范围(TTR)≥70%的接受维生素K拮抗剂(VKA)治疗的房颤患者不建议转变为接受直接口服抗凝剂治疗。本研究的目的旨在评估TTR≥70%的接受维生素K拮抗剂治疗的房颤患者以后的TTR变化及血栓或出血发生的风险。本研究纳入了数据库中接受VKA治疗后6个月的4772名房颤患者,其中1691名(35.4%)患者的TTR≥70%。在TTR≥70%且入组后12个月仍坚持治疗的患者中,仅

Stroke:INR>1.7者逆转抗凝后立即静脉溶栓

2018年10月来自法国的Nicolas Chausson等在 Stroke 上公布了他们的初步研究结果,目的在于探讨服用 VKA 且 INR>1.7的急性缺血性卒中患者逆转抗凝后立即静脉溶栓的可行性和安全性。

JAHA:维生素K拮抗剂的摄入会增加心血管疾病风险

既往研究显示,维生素K拮抗剂(VKA)的使用与血管结构和功能的损伤相关,本研究的目的旨在评估VKA的摄入与不同类型心血管疾病发生的相关性。本研究纳入了15010名35岁至74岁的研究对象,包括287名VKA使用者和14564名非VKA使用者。多变量分析结果显示,VKA的摄入与硬化指数(β=+2.54 m/s; [0.41/4.66]; P=0.019)、踝肱指数(β=−0.03; [−0.04/−

Blood:如何选择四种口服抗凝药(华法林、苊香豆醇、苯丙香豆素和氟茚二酮)?

中心点:苊香豆醇(acenocoumarol)是最有效的口服抗凝剂,在VKOR自然突变的患者中耐药变异最小。华法林和氟茚二酮具体相等的抗凝效果,但使VKOR失活的作用机制不同。摘要:华法林、苊香豆醇、苯丙香豆素和氟茚二酮是常开的口服抗凝药,用于预防和治疗血栓栓塞性疾病。这些抗凝药通过抑制维生素K环氧化物还原酶(VKOR)来降低Vit K依赖性凝血因子的生物合成来发挥作用。VKOR遗传变异与所有口服

Blood:华法林对维生素K代谢的影响

抗凝剂华法林可抑制维生素K氧化还原酶(VKORC1)的活性,VKORC1可催化合成参与维生素K依赖性(VKD)蛋白质的羧基化过程和激活。VKORC1通过两个反应催化产生KH2:将维生素K环氧化物(KO)还原成醌(K),再进一步还原成KH2;而研究人员将整体的还原反应与分解的单个反应相对比发现了一种令人惊讶的华法林抑制机制。研究人员在野生型CKORC1或导致华法林耐药的突变体(Y139H、Y139F

Baidu
map
Baidu
map
Baidu
map